胸主动脉腔内修复术治疗伴顽固性疼痛或难治性高血压的急性B型主动脉夹层的结局
本研究比较了因顽固性疼痛或难治性高血压接受胸主动脉腔内修复术(TEVAR)的无并发症急性B型主动脉夹层(UATBAD)患者与无这些特征并接受最佳药物治疗(BMT)的UATBAD患者。结果显示TEVAR安全,但与BMT相比在短期结局上无优势,尽管主动脉重塑显著改善;TEVAR组再干预率25.9% vs BMT组23%(p=0.2),生存率无差异(log-rank p=0.8)。
要点
- TEVAR组30天死亡率为0,BMT组为7%,两组无显著差异(p=0.1)。
- TEVAR组主动脉直径变化率1.5% vs BMT组12.9%(p=0.007)。
- TEVAR组完全假腔血栓形成率41% vs BMT组11%(p=0.004)。
核心结论
- 对于伴有顽固性疼痛或难治性高血压的UATBAD患者,TEVAR是安全的,但与无这些特征并接受BMT的UATBAD患者相比,未提供短期结局优势;TEVAR后主动脉重塑显著改善,但这种有利重塑的潜在长期再干预和主动脉相关死亡获益尚未明确,需要随机试验。
研究设计与样本
- 回顾性查询医院数据库,连续纳入2011年1月至2014年12月间收治的101例UATBAD患者。
- 74例接受BMT(平均年龄62±13岁;44例男性),27例因顽固性疼痛(24例,89%)和/或难治性高血压(3例,11%)在入院后平均2.4±3.3天(中位数1天,范围0-12天)接受TEVAR(平均年龄63±13岁;17例男性)。
- 采用混合模型确定中心线测量的主动脉重塑差异,采用倾向性分析减少选择偏倚,采用Kaplan-Meier法估计再干预和生存率。
主要发现
- 两组匹配良好,人口学特征、合并症或内脏受累比例(TEVAR组70% vs BMT组86%,p=0.08)无差异。
- 住院时间(TEVAR组9.6±6.3天 vs BMT组10.3±7.8天,p=0.3)、并发症(TEVAR组19% vs BMT组24%,p=0.6)或30天死亡率(TEVAR组0 vs BMT组7%,p=0.1)无显著差异。
- 1例(4%)TEVAR患者发生逆行性夹层。
- BMT组出院时抗高血压药物平均增加量更大(1.7±1.9 vs TEVAR组0.7±1.7,p=0.03),但麻醉药品使用无差异。
- TEVAR组平均随访时间更长(17.9±16.0个月 vs BMT组11.5±10.8个月,p=0.05)。
关键数值与推荐
- TEVAR组主动脉直径变化率1.5% vs BMT组12.9%(p=0.007)。
- TEVAR组完全假腔血栓形成率41% vs BMT组11%(p=0.004)。
- TEVAR组真腔扩张率85% vs BMT组7%(p<0.01)。
临床怎么用
- 对于伴有顽固性疼痛或难治性高血压的UATBAD患者,TEVAR是安全的,但与接受BMT的无这些特征患者相比未显示短期结局优势。
- TEVAR后主动脉重塑显著改善,但潜在长期再干预和主动脉相关死亡获益尚未明确,需要随机试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare uncomplicated acute type B aortic dissection (UATBAD) patients with intractable pain/refractory hypertension treated with thoracic endovascular aortic repair (TEVAR) to UATBAD subjects without these features receiving best medical therapy (BMT). METHODS: Interrogation of the hospital database identified 101 consecutive UATBAD patients admitted between January 2011 and December 2014. Of these, 74 patients (mean age 62±13 years; 44 men) were treated with BMT; the other 27 UATBAD patients (mean age 63±13 years; 17 men) were subsequently treated with TEVAR for intractable pain (24, 89%) and/or refractory hypertension (3, 11%) at a mean 2.4±3.3 days (median 1, range 0-12) after admission. Mixed models were employed to determine differences in centerline measured aortic remodeling. Propensity analysis was employed to mitigate selection bias. Kaplan-Meier methodology was used to estimate reintervention and survival. RESULTS: The groups were well matched; there was no difference in demographics, comorbidities, or proportion with visceral involvement (70% for TEVAR vs 86% for BMT, p=0.08). There was no significant difference in length of stay (9.6±6.3 for TEVAR vs 10.3±7.8 for BMT, p=0.3), complications (19% for TEVAR vs 24% for BMT, p=0.6), or 30-day mortality (0 for TEVAR vs 7% for BMT, p=0.1). One (4%) TEVAR patient experienced retrograde dissection. BMT resulted in greater mean increase in discharge antihypertensive medications (1.7±1.9 vs 0.7±1.7 for TEVAR, p=0.03), but there was no difference in narcotic utilization. Mean follow-up was greater in the TEVAR group (17.9±16.0 months) compared with BMT patients (11.5±10.8 months, p=0.05). TEVAR significantly improved rates of aortic diameter change (1.5% vs 12.9% for BMT, p=0.007), complete false lumen thrombosis (41% vs 11% for BMT, p=0.004), and true lumen expansion (85% vs 7% for BMT, p<0.01). However, there was no difference in reintervention (25.9% for TEVAR vs 23% for BMT, p=0.2) or survival (log-rank p=0.8). CONCLUSION: TEVAR for UATBAD with intractable pain/refractory hypertension is safe but offers no short-term outcome advantage when compared to UATBAD patients without these features receiving BMT. A significant improvement in aortic remodeling was identified after TEVAR. The potential long-term reintervention and aorta-related mortality benefits of this favorable remodeling have yet to be defined and randomized trials are warranted.
引用
- Laquian L, Scali ST, Beaver TM, et al. Outcomes of Thoracic Endovascular Aortic Repair for Acute Type B Dissection in Patients With Intractable Pain or Refractory Hypertension. J Endovasc Ther. 2018. PMID: 29552987. doi:10.1177/1526602818759339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。